VIP

A 28-amino-acid signalling peptide, studied as aviptadil in respiratory failure and in sarcoidosis.

What research shows

VIP is a real signalling peptide with documented immune functions, and its analogue aviptadil reached randomized trials in COVID-19 associated respiratory failure. That is an acute hospital setting. Nothing we verified supports the wellness and recovery uses it is marketed for.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.